MTPA’s Response to COVID-19

March 17, 2020

Mitsubishi Tanabe Pharma America, Inc. (MTPA) takes seriously the potential impact of COVID-19 (novel coronavirus) on the ALS community. We are committed to ensuring a safe and reliable ongoing supply of RADICAVA^® (edaravone). We are well-prepared from a product availability perspective with ample supply in the United States to meet patient needs for access to treatment.

Searchlight Support^® has a fully operational team in place and is available to provide information and guidance for healthcare providers, patients and their caregivers regarding ordering and distribution support. Anyone needing assistance should call Searchlight Support at 1-844-772-4548.

MTPA has been in contact with our main distributors. They are fully operational and have contingency plans in place for the pandemic. Be assured that the COVID-19 virus outbreak has not impacted the safe use and quality of our product. In addition, MTPA is working closely with our production facilities as part of our commitment to doing all we can to ensure our global supply chain remains uninterrupted.

Knowing that people with ALS have more complex needs, MTPA strives to help each person maintain access to infusion services. To that end, we’re maintaining regular contact with RADICAVA infusion providers regarding safety procedures and contingency plans during the pandemic. Infusion centers are maintaining standard operations. To our knowledge, infusion providers have initiated additional safety protocols to address patient care.

It’s important to reiterate that MTPA is made up of a deeply devoted team of caring and compassionate individuals. During this uncertain time, we want you to know that our U.S. field and headquarters colleagues remain working and available to help. We will continue to follow the situation closely and provide updates as needed.

Patients with medical questions should speak to their healthcare provider regarding their care and wellness during the pandemic.